# Moderna

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moderna

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.modernatx.com
- Total disclosed funding: $1.5B
- Latest round: Series G (Feb 1, 2018)
- Investors on record: 16

## About

Moderna, Inc. is an innovative biotechnology company specializing in mRNA technology, focused on developing vaccines and therapeutics to address infectious diseases and other serious health conditions.Founded in 2010 in Cambridge, US, Moderna, Inc. focuses on harnessing mRNA technology for vaccine development. The company has successfully navigated various funding rounds, including a notable Grant of USD 472.00 mn from the Biomedical Advanced Research and Development Authority. The firm's total amount raised stands at USD 472.00 mn. The founders of Moderna include Adrian Ledesma-Mendoza, Kenneth Chien, Paulina López, and Tom Walsh. The company's most recent funding round occurred in December 2018, when they raised USD 604.3 mn through an IPO.Moderna specializes in mRNA technology, focusing on a range of vaccines and therapeutic products designed to address various diseases. Their core offerings include the FDA-approved COVID-19 vaccine, Spikevax, as well as vaccines targeting seasonal influenza and respiratory syncytial virus (RSV), specifically the mRESVIA vaccine for adults aged 18-59. The company aims to harness the power of mRNA to prompt the immune system to combat diseases, providing solutions for conditions that currently lack effective treatments. Their products are primarily marketed to healthcare providers, governments, and health organizations, serving end-users such as patients in the United States, Europe, and select markets in the Asia-Pacific region. Moderna's innovative approach to rapid design and production allows them to deliver their medicines swiftly to a broad audience, ensuring accessibility and efficacy.In the most recent fiscal year 2024, Moderna reported a revenue of USD 3,236.00 mn. The company's EBITDA for the same year was USD -3,851.00 mn. Revenue is primarily generated through direct sales of its vaccines and therapeutics to healthcare providers and governments, focusing on public health initiatives through contracts with government entities and healthcare systems.Moderna is strategically focused on launching upcoming products, including additional mRNA vaccines targeting various diseases, with specific details expected in the near future. The company aims to expand its market presence beyond the United States and Europe into new regions in Asia and Latin America by 2025. The recent Grant of USD 472.00 mn will be utilized to support these product developments and market expansion initiatives.

## Funding rounds

- Series G, Feb 1, 2018, $500M — Hong Shan, Pictet Group, Alexandria Venture Investments, Abu Dhabi Investment Authority, BB Biotech, Viking Global Investors, SG Growth Capital, Fidelity Investments, Julius Baer Family Office, ArrowMark Partners
- Series F, Sep 7, 2016, $451M — Flagship Pioneering, Invus [DUP], Wellington Management, Viking Global Investors, AstraZeneca, Alexion Pharmaceuticals, Inc., RA Capital Management
- Series E, Dec 18, 2014, $450M — AstraZeneca, Invus [DUP], Wellington Management, Viking Global Investors, Fidelity Investments, Alexion Pharmaceuticals, Inc., RA Capital Management
- Series D, Nov 6, 2013, $110M — Flagship Pioneering, Fidelity Investments
- Series C, Dec 6, 2012, $17M — Flagship Pioneering
- Series B, Dec 27, 2011, $3.2M — Flagship Pioneering
- Series A, Mar 8, 2011, $2.1M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C, Series D, Series F
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series D, Series E, Series G
- AstraZeneca — Series E, Series F
- Invus [DUP] — Series E, Series F
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series E, Series F
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series E, Series F, Series G
- Alexion Pharmaceuticals, Inc. — Series E, Series F
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series E, Series F
- Hong Shan — Series G
- Pictet Group — Series G
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series G
- Abu Dhabi Investment Authority — Series G
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series G
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series G
- Julius Baer Family Office — Series G
- ArrowMark Partners — Series G